Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara, Jalisco, México; Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara, Jalisco, México.
Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara, Jalisco, México.
Med Clin (Barc). 2018 Jul 13;151(1):1-7. doi: 10.1016/j.medcli.2017.07.026. Epub 2017 Oct 7.
Lipid metabolism alterations contribute to acute coronary syndrome (ACS). rs670, rs5070 and rs693 polymorphisms have shown to modify the risk of cardiovascular disease. Apolipoprotein A-I (ApoA-I) plays a major role in reverse cholesterol transport; apolipoprotein B (ApoB) contributes to accumulation of cholesterol in the plaque. The aim of this study was to investigate the association of rs670 and rs5070 polymorphisms of APOA1 and rs693 polymorphism of APOB with ACS and circulating levels of its proteins and find if ApoB/ApoA-I could be implemented as an independent parameter of risk for cardiovascular disease and as a biomarker of lipid-lowering therapy effectiveness in Mexican population.
Three hundred patients with ACS and 300 control subjects (CS) were included.
Neither genotype nor allele frequencies of rs670, rs5070 and rs693 polymorphisms showed statistical differences between groups. Serum levels of ApoA-I (195 vs. 161.4mg/dL; P<.001) and ApoB (167 vs. 136.9mg/dL; P<.001) were significantly higher in CS compared with ACS; however, there was no genetic association. Unstable angina patients showed the highest ApoA-I levels (males: 176.3mg/dL; females: 209.1mg/dL).
The rs670, rs5070 and rs693 polymorphisms are not genetic susceptibility factors for ACS in Mexican population and had no effect on their apolipoprotein concentrations. In our population, ApoA-I, ApoB and HDL-C could be better biomarkers of cardiovascular risk and could indicate if statins doses reduce atherogenic particles properly.
脂质代谢改变与急性冠状动脉综合征（ACS）有关。rs670、rs5070 和 rs693 多态性已被证明可改变心血管疾病的风险。载脂蛋白 A-I（ApoA-I）在胆固醇逆向转运中起主要作用；载脂蛋白 B（ApoB）有助于胆固醇在斑块中的积累。本研究旨在探讨 APOA1 的 rs670 和 rs5070 多态性以及 APOB 的 rs693 多态性与 ACS 及循环蛋白水平的关系，并确定 ApoB/ApoA-I 是否可作为心血管疾病风险的独立参数以及墨西哥人群降脂治疗效果的生物标志物。
纳入 300 例 ACS 患者和 300 例对照（CS）。
rs670、rs5070 和 rs693 多态性的基因型和等位基因频率在两组间均无统计学差异。CS 组的 ApoA-I（195 与 161.4mg/dL；P<.001）和 ApoB（167 与 136.9mg/dL；P<.001）血清水平显著高于 ACS 组；然而，两者之间并无遗传关联。不稳定型心绞痛患者的 ApoA-I 水平最高（男性：176.3mg/dL；女性：209.1mg/dL）。
rs670、rs5070 和 rs693 多态性不是墨西哥人群 ACS 的遗传易感性因素，且对其载脂蛋白浓度无影响。在本人群中，ApoA-I、ApoB 和高密度脂蛋白胆固醇（HDL-C）可能是更好的心血管风险生物标志物，可指示他汀类药物剂量是否能适当减少致动脉粥样硬化颗粒。
